The third quarter financial results of Karyopharm Therapeutics (NASDAQ: KPTI) will be revealed on Tuesday 5th November 2024. The big news will come out before market open, so investors can learn more about how the company is doing financially.
In accordance with the forecasts of financial specialists on Wall Street, the concern is primed to announce an anticipated $0.26 loss per share for the quarter. Additionally, the company is projected to reveal a total revenue of $37.79 million for this particular period.
In the same three months of the year before, the company made loss of $0.3 per share, as shown in their financial report. This number came from the total revenue of $36.01 million that the company earned in that particular quarter.
Wall Street analysts have revealed their forecasts for the company's annual performance, predicting a total revenue of $152.35 million. Additionally, they expect the company to report per share loss of $0.66 for the fiscal year.
| Period | EPS Actual |
EPS Growth* |
Revenue Actual |
Revenue Growth* |
|---|---|---|---|---|
| Historical Earnings Insight | ||||
| Q2 2024 | $-0.20 | +31.0% | 42.79 M | +13.9% |
| Q1 2024 | $-0.32 | -6.7% | 33.13 M | -14.4% |
| Q4 2023 | $-0.36 | +16.3% | 33.75 M | +0.5% |
| Q3 2023 | $-0.30 | +33.3% | 36.01 M | -0.4% |
| Q2 2023 | $-0.29 | +53.2% | 37.58 M | -5.3% |
| *Growth on year-over-year basis | ||||
Additionally, The company will host a conference call with investors and analysts on 5th November 2024 at 08:00 AM eastern time to review the Q3 2024 financial results.
Karyopharm Therapeutics (KPTI) closed Friday's regular trading session at $0.90, demonstrating a 9.09 percent decline. During the day, KPTI shares traded between $0.88 and $1.02, with a day volume of 1.70 million shares.
